Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.

ABSTRACT:

Background

Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related death and represents a major health burden worldwide. Current therapies for NSCLC include chemotherapy, immunotherapy, and targeted molecular agents such as tyrosine kinase inhibitors and epigenetic drugs such as DNA methyltransferase inhibitors. However, survival rates remain low for patients with NSCLC, especially those with metastatic disease. A major cause for therapeutic failure is drug resistance, highlighting the need for novel therapies and combination strategies. Given that epigenetic modulators such as protein arginine methyltransferases (PRMTs) are frequently overexpressed in cancers, PRMT inhibitors are a promising class of cancer therapeutics. We screened a library of epigenetic and a

SUBMITTER: Dominici C 

PROVIDER: S-EPMC7948358 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature